Related references
Note: Only part of the references are listed.Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial
Peter Rossing et al.
DIABETES OBESITY & METABOLISM (2022)
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
Peter Rossing et al.
KIDNEY INTERNATIONAL REPORTS (2022)
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
Gerasimos Filippatos et al.
CIRCULATION (2021)
6. Glycemic Targets: Standards of Medical Care in Diabetes-2021
DIABETES CARE (2021)
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2021
DIABETES CARE (2021)
Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial
Joao Pedro Ferreira et al.
CIRCULATION-HEART FAILURE (2021)
Antidiabetic drug use trends in patients with type 2 diabetes mellitus and chronic kidney disease: A cross-sectional analysis of the National Health and Nutrition Examination Survey
Deval Gor et al.
JOURNAL OF DIABETES (2020)
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse et al.
DIABETOLOGIA (2020)
Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis A Multicenter Cohort Study
Antonios Douros et al.
ANNALS OF INTERNAL MEDICINE (2020)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Development of Risk Prediction Equations for Incident Chronic Kidney Disease
Robert G. Nelson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial
George L. Bakris et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
Luis M. Ruilope et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis
Sandra Korol et al.
MEDICINE (2017)
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON
Muh Geot Wong et al.
DIABETES CARE (2016)
Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials
Jie V. Zhao et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment-patterns-NHANES 2007-2012
Bingcao Wu et al.
BMJ OPEN DIABETES RESEARCH & CARE (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Link between insulin resistance and hypertension: What is the evidence from evolutionary biology?
Ming-Sheng Zhou et al.
DIABETOLOGY & METABOLIC SYNDROME (2014)
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes
Vlado Perkovic et al.
KIDNEY INTERNATIONAL (2013)
Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure
Masayuki Yamaji et al.
AMERICAN HEART JOURNAL (2010)
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
Faramarz Ismail-Beigi et al.
LANCET (2010)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Progression of nephropathy in type 2 diabetic patients
K Rossing et al.
KIDNEY INTERNATIONAL (2004)
When oral agents fail: practical barriers to starting insulin
M Korytkowski
INTERNATIONAL JOURNAL OF OBESITY (2002)